The novel antibacterial drug XF-70 is a potent inhibitor of staphylococcus aureus infection of the burn wound

Journal of Burn Care and Research

Volumn 31, Issue 3, 2010, Pages 462-469

  Hurtuk, Michael G ^a   He, L K ^a   Szilagyi, Andrea ^a   Gamelli, Richard L ^a   Hecht, David W ^a   Kennedy, Richard H ^a   Rhys Williams, William ^b   Love, William G ^b   Shankar, Ravi ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Destiny Pharma Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; SULFADIAZINE SILVER; UNCLASSIFIED DRUG; XF 70;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BURN; BURN INFECTION; COLONY FORMING UNIT; CONTROLLED STUDY; IN VIVO STUDY; INOCULATION; MALE; MOUSE; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ADMINISTRATION, TOPICAL; ANALYSIS OF VARIANCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; BURNS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MALE; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; POLYESTERS; POLYETHYLENES; PORPHYRINS; SILVER SULFADIAZINE; SPLEEN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; WOUND INFECTION;

EID: 77952294247     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e3181db5265     Document Type: Article

References (46)

1. Latenser BA, Miller SF, Bessey PQ, et al. National Burn Repository 2006: Report of Dataset Version 3.0. J Burn Care Res 2007;28:635-658.
2. Pruitt BA Jr, O'Neill JA Jr, Moncrief JA, Lindberg RB. Successful control of burn-wound sepsis. JAMA 1968;203:1054-6.
3. Wallace BH, Caldwell FT Jr, Cone JB. The interrelationships between wound management, thermal stress, energy metabolism, and temperature profiles of patients with burns. J Burn Care Rehabil 1994;15:499-508.
4. Order SE, Mason AD Jr, Switzer WE, Moncrief JA. Arterial vascular occlusion and devitalization of burn wounds. Ann Surg 1965;161:502-8.
5. Hoffman LR, D'Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005;436:1171-5.
6. Griffith RS. Introduction to vancomycin. Rev Infect Dis 1981;3(Suppl): S200-04.
7. Hanaki H, Hiramatsu K. [Emerging infectious and drugresistant diseases-vancomycin resistant gram-positive cocci]. Nippon Naika Gakkai Zasshi 1997;86:2075-80.
8. Neely AN, Gardner J, Durkee P, et al. Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics? J Burn Care Res 2009;30:19-29.
9. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6:29-40.
10. Ooi N, Rhys-Willioams W, Love W, Chopra I. Comparison of bacterial membrane active novel porphyrin and mettaloporphrin antimicrobials. 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Helsinki, Finland; 2009.
11. Ooi N, Miller K, Hobbs J. XF-73, a novel anti-staphylococcal membrane active agent with rapid bactericidal activity. J Antimicrob Chemother 2010;65:72-78.
12. Love W, Rhys-Williams W, Hayter I, Farrell D, Curry J, Robbins M. XF-73, a novel antimicrobial with broad ranging Gram positive antibacterial activity. 18th European Congress of Clinical Microbiology and Infectious Diseases (ESSMID). Vol. 14 Helsinki, Finland; 2008: S130-31.
13. Love W, Rhys-Williams W, Hayter I, Farrell D, Janes R, Robbins M. XF-73: a new antimicrobial drug-comparison with daptomycin for the development of mutational resistance in MRSA USA300 ina55-passage study. 48th Annual ICAAC/IDSA Meeting, Washington DC; 2008: poster F1-3970.
14. Rhys-Williams W, Love W, Hayter I, et al. XF-73: a novel antimicrobial-investigation of the change in MIC against multiple MRSA strains during a 55-passage study. 18th European Congress of Clinical Microbiology and Infectious Diseases (ESSMID). Vol. 14. Helsinki, Finland; 2008: S130.
15. Miller K, Randall C, Love WG, Hayter I, Rhys-Williams W, Chopra I. XF-73: a new antimicrobial drug, active against biofilms and slow growing cultures of Staphylococcus aureus. 48th Annual ICAAC/IDSA Meeting. Washington, DC; 2008: poster F1-3968.
16. Maisch T, Bosl C, Szeimies RM, Lehn N, Abels C. Photodynamic effects of novel XF porphyrin derivatives on prokaryotic and eukaryotic cells. Antimicrob Agents Chemother 2005;49:1542-52.
17. Walker HL, Mason AD Jr. A standard animal burn. J Trauma 1968;8:1049-51.
18. Pruitt BA Jr, McManus AT, Kim SH, Goodwin CW. Burn wound infections: current status. World J Surg 1998;22:135-45.
19. Liedberg NC, Reiss E, Kuhn LR, Amspacher WH, Artz CP. Infection in burns. IV. Evaluation of the local use of chloramphenicol ointment and furacin soluble dressing on granulating surfaces following extensive full thickness burns. Surg Gynecol Obstet 1955;100:219-31.
20. Takahashi H, Tsuda Y, Takeuchi D, Kobayashi M, Herndon DN, Suzuki F. Influence of systemic inflammatory response syndrome on host resistance against bacterial infections. Crit Care Med 2004;32:1879-85.
21. Bishop WJ. The early history of surgery. Hale Ltd, London; 1960.
22. Bergmark M. In: Vallort och Vitlok: om Folkmedinens Lakeorter. Stockholm; 1967.
23. Forrest RD. Early history of wound treatment. J R Soc Med 1982;75:198-205.
24. Lindberg RB, Moncrief JA, Switzer WE, Order SE, Mills W Jr. The successful control of burn wound sepsis. J Trauma 1965;5:601-16.
25. Martineau L, Davis SC, Peng HT, Hung A. Controlling methicillin resistant Staphyloccocus aureus and Pseudomonas aeruginosa wound infections with a novel biomaterial. J Invest Surg 2007;20:217-27.
26. Kucan JO, Smoot EC. Five percent mafenide acetate solution in the treatment of thermal injuries J Burn Care Rehabil 1993;14:158-63.
27. Zapata-Sirvent RL, Hansbrough JF. Cytotoxicity to human leukocytes by topical antimicrobial agents used for burn care. J Burn Care Rehabil 1993;14:132-40.
28. Cooper ML, Laxer JA, Hansbrough JF. The cytotoxic effects of commonly used topical antimicrobial agents on human fibroblasts and keratinocytes. J Trauma 1991;31:775-82; discussion 782-4.
29. Zhang XJ, Heggers JP, Chinkes DL, Wolf SE, Hawkins HK, Wolfe RR. Topical Sulfamylon cream inhibits DNA and protein synthesis in the skin donor site wound. Surgery 2006;139:633-9.
30. Fox CL Jr. Silver sulfadiazine-a new topical therapy for Pseudomonas in burns. Therapy of Pseudomonas infection in burns. Arch Surg 1968;96:184-8.
31. Chaby G, Viseux V, Poulain JF, De Cagny B, Denoeux JP, Lok C. [Topical silver sulfadiazine-induced acute renal failure]. Ann Dermatol Venereol 2005;132:891-3.
32. Trop M. Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J Trauma 2006;61:1024.
33. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982;4:426-8.
34. Filius PM, Gyssens IC. Impact of increasing antimicrobial resistance on wound management. Am J Clin Dermatol 2002;3:1-7.
35. Howell-Jones RS, Wilson MJ, Hill KE, Howard AJ, Price PE, Thomas DW. A review of the microbiology, antibiotic usage and resistance in chronic skin wounds. J Antimicrob Chemother 2005;55:143-9.
36. Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother 2003;51:613-7.
37. Jelenko C III. Silver nitrate resistant E. coli: report of case. Ann Surg 1969;170:296-9.
38. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005;56:20-51.
39. Silver S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol Rev 2003;27:341-53.
40. Silver S, Phung le T, Silver G. Silver as biocides in burn and wound dressings and bacterial resistance tosilver compounds. J Ind Microbiol Biotechnol 2006;33:627-34.
41. Percival SL, Bowler PG, Russell D. Bacterial resistance to silver in wound care. J Hosp Infect 2005;60:1-7.
42. Hornef MW, Wick MJ, Rhen M, Normark S. Bacterial strategies for overcoming host innate and adaptive immune responses. Nat Immunol 2002;3:1033-40.
43. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318-22.
44. Shankar R, He LK, Szilagyi A, et al. A novel antibacterial gene transfer treatment for multidrug-resistant Acinetobacter baumannii-induced burn sepsis. J Burn Care Res 2007;28:6-12.
45. Miller K, Ooi N, Hobbs JK, et al. XF-73, a novel antistaphylococcal antimicrobial with very rapid bactericidal activity. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain; 2008: S130-31.
46. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520-32.